Vaccine-Chemo combo shows promise against spread prostate cancer

NCT ID NCT02649855

Completed Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding a prostate cancer vaccine (PROSTVAC) and chemotherapy (docetaxel) to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. 74 men with metastatic castration-sensitive prostate cancer took part. The goal was to see if the combination could boost the immune system's ability to fight the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PROSTVAC (a vaccine made from viruses that trains the immune system to attack prostate cancer cells) and docetaxel (a chemotherapy drug)
What this could lead to: If it works, this could point toward a more effective combination treatment for metastatic prostate cancer that harnesses the immune system.
What could go wrong: This is a small, early-phase (Phase 2) study with only 74 participants, so results may not apply to all patients. The vaccine and chemo combination may cause side effects like fatigue, infection, or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS, PROSTATIC PROSTATE CANCER PROSTATE NEOPLASMS

Contacts and locations

Locations

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.